Other map-K pathway driven diseases

Clinical trials for Other map-K pathway driven diseases explained in plain language.

Never miss a new study

Get alerted when new Other map-K pathway driven diseases trials appear

Sign up with your email to follow new studies for Other map-K pathway driven diseases, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Last-Resort drug access opens for rare tumor patients

Disease control Expanded access

This program provides mirdametinib to individual patients with serious, life-threatening conditions like neurofibromatosis type 1 tumors or other MAP-K pathway diseases who have no other treatment options and cannot join a clinical trial. Each case requires approval from the comp…

Matched conditions: OTHER MAP-K PATHWAY DRIVEN DISEASES

Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control

Last updated Jun 27, 2026 12:31 UTC

Other map-K pathway driven diseases

Get alerted when new Other map-K pathway driven diseases trials appear

Last-Resort drug access opens for rare tumor patients